MPM BioImpact-Backed Aktis Seeks $212 Million in US IPO

Aktis Oncology Inc., a clinical-stage biotechnology company focused on using so-called radiopharmaceuticals for treatments, is seeking to raise as much as $212 million in a US initial public offering.

The firm, backed by MPM BioImpact and Vida Ventures, plans to sell 11.8 million shares at $16 to $18 each, according to its Monday filing with the US Securities and Exchange Commission. The offering is expected to price on Jan. 8, according to a marketing presentation.